Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.rlc completes German PHARMACENTER expansion
The new production facility with doubled machine capacity is designed to meet the growing demand for pharmaceutical packaging, according to the company. The PHARMACENTER, which provides filling and
The new production facility with doubled machine capacity is designed to meet the growing demand for pharmaceutical packaging, according to the company. The PHARMACENTER, which provides filling and
The company in the past has received the final approval for Fenofibrate tablets from the US Food and Drug Administration. The released tablets are the AB rated generic,
The recent studies have also shown that EP-AD test may also capture the transition from normal aging to mild cognitive impairment, according to the company. The EP-AD diagnostic
As part of the agreement, Shire will make an initial upfront payment to Boston Children’s and also fund selected research programs. The duo will primarily focus on treatment
The company will use the finance to expand its comprehensive suite of software products and services. Horizon president Gerald Michaud said, "We are pleased to provide this venture
Incorporating a preconfigured system that answers various pharma-specific use cases, the Planisware Prime for Pharma solution helps clients to gain real-time visibility into their portfolio and resources. The
The second-generation anticancer agent with a dual-mechanism vascular disrupting feature integrates vascular disrupting activity and direct cytotoxicity. With the issuance of orphan drug designation, the company gains market
The terms of the deal that also involves marketing of the extended topical generic product were not revealed. Impax Laboratories president and CEO Larry Hsu said, "In just
Aubagio, which has anti-inflammatory properties, is expected to minimize activated lymphocyte count in the central nervous system. Genzyme multiple sclerosis head Bill Sibold said with the TGA approval
According to the study data, the AB103 administered patients demonstrated a meaningful improvement across multiple endpoints compared to placebo. The University of Washington Harborview Medical Center professor of